Article Text

Download PDFPDF
Invasive aspergillosis complicating treatment with tyrosine kinase inhibitors
  1. Tajwar Nasir1,
  2. Claudia Lee1,
  3. Alexandra SC Lawrence2 and
  4. Jeremy S Brown3
  1. 1 Respiratory Division of Medicine, University College London Medical School, London, UK
  2. 2 Respiratory Division of Medicine, University College London Hospital, London, UK
  3. 3 Respiratory Division of Medicine, University College London, London, UK
  1. Correspondence to Professor Jeremy S Brown, jeremy.brown{at}


We describe three cases of pulmonary aspergillosis (PA) in three patients without traditional risk factors for invasive aspergillosis infection, such as prolonged neutropenia or high dose systemic corticosteroid therapy. All three patients developed PA while taking tyrosine kinase inhibitors (TKI) and sustained greater clinical improvement once TKI were withdrawn. Our case series supports the theory TKI treatment can increase susceptibility to PA without causing neutropenia. Recognition that TKI treatment may predispose to invasive aspergillosis will allow for rapid recognition of affected patients and more effective management of future cases.

  • drugs: respiratory system
  • haematology (drugs and medicines)
  • infections
  • malignant disease and immunosuppression

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Patient consent for publication Obtained.

  • Contributors Tajwar Nasir, Claudia Lee and Alexandra Lawrence each helped to obtain clinical information and images for the case reports and wrote the body of the manuscript. Jeremy Brown developed the hypothesis and provided guidance for writing and final review of the article prior to submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.